Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Want to see KPRX full AI Analyst Report?
KPRX Stock Chart & Stats
$1.91
-$0.13(-3.22%)
At close: 4:00 PM EST
$1.91
-$0.13(-3.22%)
Day’s Range― - ―
52-Week Range$1.76 - $4.18
Previous CloseN/A
Volume13.46K
Average Volume (3M)36.18K
Market Cap
$11.70M
Enterprise Value$1.12M
Total Cash (Recent Filing)$13.87M
Total Debt (Recent Filing)$373.59K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 07, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding4,431,940
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.94
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$12.00Price Target Upside528.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Limited DebtVery low debt reduces near-term solvency risk for a cash-burning clinical-stage biotech. With minimal leverage, the company retains strategic optionality to raise capital or partner without immediate default risk, preserving runway flexibility over the next several months.
Committed Financing With Upside Via WarrantsThe $5M upfront proceeds materially extend near-term runway and the attached milestone- and exercise-linked warrants provide contingent funding tied to development progress. This structure reduces immediate financing urgency and aligns investor incentives with trial milestones.
Clinical Programs Continuing Enrollment And Safety ClearancesOngoing enrollment and cleared safety checkpoints demonstrate executional continuity for core retinal programs. Sustained trial progress preserves potential value inflection points and supports the company’s strategic objective of advancing candidates toward later-stage trials.
Bears Say
Revenue Collapse And Volatile EarningsThe abrupt fall to zero reported revenue and a meaningful TTM net loss indicate an unstable revenue model and high execution risk. Without commercial sales, the company depends entirely on financing and partnerships, increasing sensitivity to trial setbacks and lengthening time to self-sustaining margins.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow show that losses translate to real cash burn rather than non-cash charges. Persistent outflows necessitate repeat external funding, heightening dilution risk and constraining the company’s ability to scale trials or invest in parallel programs without new financing.
Erosion Of Capital Base Despite Low DebtDeclining equity and assets indicate the balance sheet cushion is shrinking, reducing capacity to absorb operational setbacks. Even with low debt, capital erosion raises the probability of future dilutive financings or strategic transactions to replenish resources, pressuring long-term financial flexibility.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.76 and its highest was $4.18 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $11.70M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on May 08, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.71 by $0.13.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.47.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 4,431,940 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.71. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(528.27% Upside)
Technical Analysis
Genprex
―
Dogwood Therapeutics
―
Sensei Biotherapeutics
―
TransCode Therapeutics
―
AEON Biopharma
―
Ownership Overview
2.69% Insiders
1.05% Mutual Funds
4.02% Other Institutional Investors
91.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---